CERENOME, INC. — Form 8-K
Filed September 10, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 67/100
What the filing says
Cerenome issued Senior Secured Convertible Notes totaling $21,276,596 across three tranches: Initial Notes of $3,191,489, Second Notes of $2,127,660, and Additional Notes of $15,957,447. Notes bear 8% interest with 6% original issue discount, convert at prices ranging from $2.74 to 110% of Nasdaq minimum price, and amortize quarterly starting three months post-closing. Maturity is one year from initial closing, extendable if CNSide CSF test sales reach $10M by Q2 2027 or upon events of default.
Why this rating
Material financing for micro-cap ($31.9M market value); $21.3M represents 67% of market cap. Secured structure, conversion dilution, and staged funding with performance conditions are material but typical for early-stage biotech. Pending stockholder approval critical.
See more from September 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.